Medical Tidbits, Leading Medical News Today

Your place for beaking medical news and career advice from top medical recruiters

Amgen Enters Into Neuroscience Collaboration With Novartis For Alzheimer’s Disease And Migraine Programs

THOUSAND OAKS, Calif., Sept. 1, 2015 /PRNewswire/ — Amgen (NASDAQ:AMGN) today announced a neuroscience collaboration with Novartis in the areas of Alzheimer’s disease and migraine. The collaboration accelerates Amgen’s potential entry into Alzheimer’s disease by teaming up with Novartis on a differentiated and genetically validated Alzheimer’s disease program directed at genetically predisposed individuals at risk of developing Alzheimer’s disease. The collaboration also enables Amgen to focus on the commercialization of its migraine programs in the U.S., Canada and Japan, while leveraging Novartis’ strong commercial capabilities in neuroscience throughout Europe and other markets worldwide. read more

ADC Therapeutics Secures $80m Financing to Progress Its Pipeline of Antibody Drug Conjugate Therapeutics in Oncology

LAUSANNE, Switzerland & LONDON & MURRAY HILL, N.J.–(EON: Enhanced Online News)–ADC Therapeutics (ADCT), an oncology drug discovery and development company that specializes in the development of proprietary Antibody Drug Conjugates (ADCs) targeting major cancers, today announced that it has raised $80 million through a private placement of equity. New investors include leading European and US-based investors alongside founding investor Auven Therapeutics and participation from AstraZeneca. read more

Incyte Announces Global License Agreement with Jiangsu Hengrui Medicine for SHR-1210, an Investigational Anti-PD-1 Monoclonal Antibody

WILMINGTON, Del.–(EON: Enhanced Online News)–Incyte Corporation (Nasdaq: INCY) today announced a global license and collaboration agreement with Jiangsu Hengrui Medicine Co., Ltd. for the development and commercialization of SHR-1210, an investigational anti-PD-1 monoclonal antibody. Under the agreement, Incyte will have the exclusive development and commercialization rights to SHR-1210 worldwide, with the exception of Mainland China, Hong Kong, Macau, and Taiwan. SHR-1210 is expected to enter proof-of-concept studies for the treatment of patients with advanced solid tumors in the coming months. read more

Titan Spine Enters Distribution Agreement with MBA to Expand Endoskeleton® Titanium Implant Portfolio Offering in Europe

MEQUON, Wis.–(EON: Enhanced Online News)–Titan Spine, a medical device surface technology company focused on developing innovative spinal interbody fusion implants, today announced that it has entered into a distribution agreement with MBA as a strategic partner to provide Titan’s line of Endoskeleton® titanium implants to practicing spine surgeons in six countries across Europe. Under the agreement, Titan Spine will provide its spinal interbody fusion devices featuring its proprietary surface technology to MBA for distribution in Spain, Portugal, Andorra, Luxembourg, Belgium and the United Kingdom (UK). MBA is a prominent international medical device marketing-and-distribution organization that specializes in the sale of products used for orthopedic and neurosurgery treatments. read more

Novartis receives EU approval for new Revolade® use as first-in-class therapy for patients with severe aplastic anemia

Basel, September 2, 2015 – Novartis announced today that the European Commission has approved Revolade® (eltrombopag) for the treatment of adults with severe aplastic anemia (SAA) who were either refractory to prior immunosuppressive therapy or heavily pretreated and are unsuitable for hematopoietic stem cell transplant. read more

For leading medical news and career advice in the medical field subscribe to Med Career News.





Get Med Career News in your Inbox!

If you want to keep up with the latest news and career tips in the Medical Field subscribe today!

Subscribe to Blog via Email

Enter your email address to subscribe to this blog and receive notifications of new posts by email.